Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c

Published:2017-10-05 Issue:2 Volume:20 Page:409-418
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Gallwitz Baptist¹,Dagogo‐Jack Samuel²,Thieu Vivian³,Garcia‐Perez Luis‐Emilio³^ORCID,Pavo Imre⁴,Yu Maria⁵,Robertson Kenneth E.³,Zhang Nan³,Giorgino Francesco⁶

Affiliation:

1. University of Tübingen Tübingen Germany

2. University of Tennessee Health Science Center Memphis Tennessee

3. Lilly DiabetesEli Lilly and Company Indianapolis Indiana

4. Eli Lilly Regional Operations Vienna Austria

5. Eli Lilly Canada Toronto Canada

6. University of Bari Aldo Moro Bari Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13086

Reference25 articles.

1. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

2. Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

3. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

4. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

5. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus;Endocrine;2024-08-23

2. Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance;International Journal of Molecular Sciences;2024-08-08

3. Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study;Diabetes & Metabolism Journal;2024-05-31

4. Comparing Efficacy and Safety of Glucagon-Like Peptide 1 (GLP-1) Agonist Versus Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Chinese Patients with Type 2 Diabetes Mellitus: A Preliminary Study;International Journal of Pharmacology;2024-05-01

5. Typ-2-Diabetes: Auch das Geschlecht berücksichtigen;CME;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3